Cullinan Therapeutics to Participate in Fireside Chat at Stifel 2024 Healthcare Conference
Cullinan Therapeutics (Nasdaq: CGEM) announced its participation in the Stifel 2024 Healthcare Conference in New York. The company's CEO Nadim Ahmed and CMO Jeffrey Jones will engage in a fireside chat on Tuesday, November 19, 2024, at 1:50 p.m. ET. The event will be accessible via webcast through the company's investor relations website under the Events and Presentations section. Cullinan is a biopharmaceutical company that specializes in developing modality-agnostic targeted therapies.
Cullinan Therapeutics (Nasdaq: CGEM) ha annunciato la sua partecipazione alla Stifel 2024 Healthcare Conference a New York. Il CEO dell'azienda, Nadim Ahmed, e il CMO, Jeffrey Jones, parteciperanno a una chiacchierata informale il martedì 19 novembre 2024, alle 13:50 ET. L'evento sarà accessibile tramite webcast attraverso il sito web delle relazioni con gli investitori dell'azienda, nella sezione Eventi e Presentazioni. Cullinan è una società biotecnologica che si specializza nello sviluppo di terapie mirate indipendenti dalla modalità.
Cullinan Therapeutics (Nasdaq: CGEM) anunció su participación en la Conferencia de Salud Stifel 2024 en Nueva York. El CEO de la empresa, Nadim Ahmed, y el CMO, Jeffrey Jones, participarán en una charla informal el martes 19 de noviembre de 2024, a la 1:50 p.m. ET. El evento será accesible a través de una transmisión en línea en el sitio web de relaciones con inversores de la empresa, en la sección de Eventos y Presentaciones. Cullinan es una empresa biofarmacéutica que se especializa en el desarrollo de terapias dirigidas independientes de la modalidad.
Cullinan Therapeutics (Nasdaq: CGEM)는 뉴욕에서 열리는 Stifel 2024 Healthcare Conference에 참가한다고 발표했습니다. 회사의 CEO인 Nadim Ahmed와 CMO인 Jeffrey Jones는 2024년 11월 19일 화요일, 오후 1시 50분 ET에 화로 모임에서 대화할 예정입니다. 이 행사는 회사의 투자자 관계 웹사이트의 이벤트 및 발표 섹션을 통해 웹캐스트로 접근할 수 있습니다. Cullinan은 모달리티에 구애받지 않는 표적 치료제를 개발하는 생명공학 회사입니다.
Cullinan Therapeutics (Nasdaq: CGEM) a annoncé sa participation à la Stifel 2024 Healthcare Conference à New York. Le PDG de l'entreprise, Nadim Ahmed, et le CMO, Jeffrey Jones, participeront à une discussion informelle le mardi 19 novembre 2024, à 13h50 ET. L'événement sera accessible par webcast via le site de relations investisseurs de l'entreprise, dans la section Événements et Présentations. Cullinan est une entreprise biopharmaceutique spécialisée dans le développement de thérapies ciblées indépendantes de la modalité.
Cullinan Therapeutics (Nasdaq: CGEM) gab seine Teilnahme an der Stifel 2024 Healthcare Conference in New York bekannt. Der CEO des Unternehmens, Nadim Ahmed, und der CMO, Jeffrey Jones, werden am Dienstag, den 19. November 2024, um 13:50 Uhr ET an einem Gespräch teilnehmen. Die Veranstaltung wird über einen Webcast über die Investor-Relations-Website des Unternehmens in der Sektion Veranstaltungen und Präsentationen zugänglich sein. Cullinan ist ein biopharmazeutisches Unternehmen, das sich auf die Entwicklung von modalitätsunabhängigen zielgerichteten Therapien spezialisiert hat.
- None.
- None.
CAMBRIDGE, Mass., Nov. 05, 2024 (GLOBE NEWSWIRE) -- Cullinan Therapeutics, Inc. (Nasdaq: CGEM; “Cullinan”), a biopharmaceutical company focused on developing modality-agnostic targeted therapies, today announced that Nadim Ahmed, Chief Executive Officer, and Jeffrey Jones, M.D., M.B.A., Chief Medical Officer, will participate in a fireside chat at the Stifel 2024 Healthcare Conference, being held in New York on November 18 and 19, 2024.
The fireside chat is scheduled for Tuesday, November 19, 2024, at 1:50 p.m. ET. A webcast of the fireside chat will be available under the Events and Presentations section of the Company’s investor relations website at https://cullinantherapeutics.com/events-and-presentations/.
About Cullinan Therapeutics
Cullinan Therapeutics, Inc. (Nasdaq: CGEM) is a biopharmaceutical company dedicated to creating new standards of care for patients. Cullinan has strategically built a diversified portfolio of clinical-stage assets that inhibit key drivers of disease or harness the immune system to eliminate diseased cells in both autoimmune diseases and cancer. Cullinan’s portfolio encompasses a wide range of modalities, each with the potential to be best and/or first in class. Anchored in a deep understanding of oncology, immunology, and translational medicine, we create differentiated ideas, identify the most appropriate targets, and select the optimal modality to develop transformative therapeutics across a wide variety of autoimmune and cancer indications. We push conventional boundaries from candidate selection to differentiated therapeutic, applying rigorous go/no go criteria at each stage of development to fast-track only the most promising molecules to the clinic and, ultimately, commercialization. With deep scientific expertise, our teams exercise creativity and urgency to deliver on our promise to bring new therapeutic solutions to patients. Learn more about Cullinan at https://cullinantherapeutics.com/, and follow us on LinkedIn and X.
Contacts:
Investor Relations
Nick Smith
+1 401.241.3516
nsmith@cullinantx.com
Media
Rose Weldon
+1 215.801.7644
rweldon@cullinantx.com
FAQ
When is Cullinan Therapeutics (CGEM) presenting at the Stifel 2024 Healthcare Conference?
Where can I watch Cullinan Therapeutics (CGEM) fireside chat at the Stifel Conference?
Which executives from Cullinan Therapeutics (CGEM) will participate in the Stifel 2024 Healthcare Conference?
Where is the Stifel 2024 Healthcare Conference featuring Cullinan Therapeutics (CGEM) being held?
